269 related articles for article (PubMed ID: 23170306)
21. Glucarpidase for methotrexate nephrotoxicity: another string to our bow.
Koratala A; Ruchi R
Intern Med J; 2017 Nov; 47(11):1327. PubMed ID: 29105263
[No Abstract] [Full Text] [Related]
22. Glucarpidase treatment for methotrexate intoxication: a case report and review of the literature.
Boelens AD; Mathôt RAA; Vlaar APJ; Bouman CSC
Neth J Med; 2018 Jan; 76(1):36-39. PubMed ID: 29380731
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic Drug Monitoring of Methotrexate in Plasma Using Ultra High-Performance Liquid Chromatography-Electrospray Ionization-Tandem Mass Spectrometry: Necessary After Administration of Glucarpidase in Methotrexate Intoxications.
Mulder MB; Huisman R; Engels FK; van der Sluis IM; Koch BCP
Ther Drug Monit; 2018 Aug; 40(4):383-385. PubMed ID: 29994985
[TBL] [Abstract][Full Text] [Related]
24. Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients.
Christensen AM; Pauley JL; Molinelli AR; Panetta JC; Ward DA; Stewart CF; Hoffman JM; Howard SC; Pui CH; Pappo AS; Relling MV; Crews KR
Cancer; 2012 Sep; 118(17):4321-30. PubMed ID: 22252903
[TBL] [Abstract][Full Text] [Related]
25. Successful carboxypeptidase G2 rescue in delayed methotrexate elimination due to renal failure.
Zoubek A; Zaunschirm HA; Lion T; Fischmeister G; Vollnhofer G; Gadner H; Pillwein K; Schalhorn A; Bode U
Pediatr Hematol Oncol; 1995; 12(5):471-7. PubMed ID: 8519632
[TBL] [Abstract][Full Text] [Related]
26. Successful Treatment of Delayed Methotrexate Clearance Using Glucarpidase Dosed on Ideal Body Weight in Obese Patients.
Krüger C; Engel N; Reinert J; Alsdorf W; Fiedler W; Dierlamm J; Bokemeyer C; Langebrake C
Pharmacotherapy; 2020 May; 40(5):479-483. PubMed ID: 32239519
[TBL] [Abstract][Full Text] [Related]
27. [Carboxypeptidase-G2-rescue in a woman with methotrexate-induced renal failure].
von Poblozki A; Dempke W; Schmoll HJ
Med Klin (Munich); 2000 Aug; 95(8):457-60. PubMed ID: 10985069
[TBL] [Abstract][Full Text] [Related]
28. Effective removal of methotrexate by high-flux hemodialysis.
Saland JM; Leavey PJ; Bash RO; Hansch E; Arbus GS; Quigley R
Pediatr Nephrol; 2002 Oct; 17(10):825-9. PubMed ID: 12376811
[TBL] [Abstract][Full Text] [Related]
29. [Renal toxicity of high-dose methotrexate].
Garcia H; Leblond V; Goldwasser F; Bouscary D; Raffoux E; Boissel N; Broutin S; Joly D
Nephrol Ther; 2018 Apr; 14 Suppl 1():S103-S113. PubMed ID: 29606256
[TBL] [Abstract][Full Text] [Related]
30. Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction.
Widemann BC; Balis FM; Murphy RF; Sorensen JM; Montello MJ; O'Brien M; Adamson PC
J Clin Oncol; 1997 May; 15(5):2125-34. PubMed ID: 9164227
[TBL] [Abstract][Full Text] [Related]
31. Rescue of experimental intrathecal methotrexate overdose with carboxypeptidase-G2.
Adamson PC; Balis FM; McCully CL; Godwin KS; Bacher JD; Walsh TJ; Poplack DG
J Clin Oncol; 1991 Apr; 9(4):670-4. PubMed ID: 2066764
[TBL] [Abstract][Full Text] [Related]
32. Methotrexate nephrotoxicity: Novel treatment, new approach.
Iqbal S; Armaghani A; Aiyer R; Kazory A
J Oncol Pharm Pract; 2013 Dec; 19(4):373-6. PubMed ID: 24255083
[TBL] [Abstract][Full Text] [Related]
33. Extended duration of prehydration does not prevent nephrotoxicity or delayed drug elimination in high-dose methotrexate infusions: a prospectively randomized cross-over study.
Mikkelsen TS; Mamoudou AD; Tuckuviene R; Wehner PS; Schroeder H
Pediatr Blood Cancer; 2014 Feb; 61(2):297-301. PubMed ID: 24039194
[TBL] [Abstract][Full Text] [Related]
34. Outcomes Associated with Reducing the Urine Alkalinization Threshold in Patients Receiving High-Dose Methotrexate.
Drost SA; Wentzell JR; Giguère P; McLurg DL; Sabloff M; Kanji S; Nguyen TT
Pharmacotherapy; 2017 Jun; 37(6):684-691. PubMed ID: 28394433
[TBL] [Abstract][Full Text] [Related]
35. Resumption of high-dose methotrexate after methotrexate-induced nephrotoxicity and carboxypeptidase G2 use.
Snyder RL
Am J Health Syst Pharm; 2007 Jun; 64(11):1163-9. PubMed ID: 17519458
[TBL] [Abstract][Full Text] [Related]
36. Incidence and management of patients with methotrexate delayed elimination in the clinical practice: A Delphi study.
Gros L; Roldán A; Cabero-Martínez A; Domínguez-Pinilla N; de la Fuente A; González-Barca E; Tasso M; Torrent M; Gallardo E; Del Cerro I; Giró-Perafita A; Badia X
J Oncol Pharm Pract; 2023 Jun; 29(4):794-801. PubMed ID: 35147457
[TBL] [Abstract][Full Text] [Related]
37. Intravenous radiographic contrast administered prior to high-dose methotrexate and subsequent toxicity requiring the use of glucarpidase.
Schultz TE; Lynch AC
J Oncol Pharm Pract; 2019 Jun; 25(4):993-997. PubMed ID: 29651915
[TBL] [Abstract][Full Text] [Related]
38. Treatment of methotrexate intoxication with various modalities of continuous extracorporeal therapy and glucarpidase.
Vilay AM; Mueller BA; Haines H; Alten JA; Askenazi DJ
Pharmacotherapy; 2010 Jan; 30(1):111. PubMed ID: 20030480
[TBL] [Abstract][Full Text] [Related]
39. Carboxypeptidase-G2 rescue in cancer patients with delayed methotrexate elimination after high-dose methotrexate therapy.
Krause AS; Weihrauch MR; Bode U; Fleischhack G; Elter T; Heuer T; Engert A; Diehl V; Josting A
Leuk Lymphoma; 2002 Nov; 43(11):2139-43. PubMed ID: 12533039
[TBL] [Abstract][Full Text] [Related]
40. Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure.
Buchen S; Ngampolo D; Melton RG; Hasan C; Zoubek A; Henze G; Bode U; Fleischhack G
Br J Cancer; 2005 Feb; 92(3):480-7. PubMed ID: 15668713
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]